Maarten Cozijnsen

91 Chapter 4 Infliximab impacts leukocyte RNA expression and serum inflammatory proteins Supplementary table 1. Continued Protein Infliximab treated patients Prednisolone treated patients Fold change (mean) False discovery rate Fold change (mean) False discovery rate Interleukin-17A (IL-17A) -0.27 0.265 -0.01 0.903 Interleukin-2 (IL-2) -0.07 0.297 -0.07 0.410 Thymic stromal lymphopoietin (TSLP) -0.14 0.334 -0.03 0.708 Interleukin-20 receptor subunit alpha (IL- 20RA) -0.17 0.352 -0.14 0.350 Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) -0.28 0.352 -0.23 0.708 TNF-related activation-induced cytokine (TRANCE) 0.40 0.352 0.09 0.799 Macrophage colony-stimulating factor 1 (CSF-1) -0.41 0.386 0.04 0.799 Interleukin-22 receptor subunit alpha-1 (IL-22 RA1) 0.11 0.386 0.00 1.000 Interleukin-33 (IL-33) -0.13 0.386 -0.05 0.708 Artemin (ARTN) -0.13 0.391 -0.16 0.531 Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) -0.50 0.435 2.02 0.350 C-C motif chemokine 19 (CCL19) -0.15 0.435 -0.22 0.903 Fractalkine (CX3CL1) 0.17 0.435 0.27 0.531 Interleukin-5 (IL-5) 0.25 0.435 -0.26 0.628 Delta and Notch-like epidermal growth factor- related receptor (DNER) 0.12 0.560 -0.09 0.708 Interleukin-10 receptor subunit alpha (IL-10RA) -0.09 0.560 0.16 0.799 TNF-related apoptosis-inducing ligand (TRAIL) -0.21 0.560 -0.26 0.799 Adenosine Deaminase (ADA) -0.17 0.690 1.32 0.350 Neurturin (NRTN) -0.09 0.690 -0.08 0.414 Neurotrophin-3 (NT-3) 0.12 0.690 -0.06 0.799 Urokinase-type plasminogen activator (uPA) -0.12 0.690 0.00 0.903 Leukemia inhibitory factor (LIF) -0.06 0.766 -0.27 0.350 Beta-nerve growth factor (Beta-NGF) -0.39 0.787 0.41 0.903 C-C motif chemokine 25 (CCL25) -0.03 0.787 -0.19 0.708 Fibroblast growth factor 23 (FGF-23) 0.15 0.787 -0.02 0.799 Interleukin-10 (IL-10) 0.44 0.787 -0.51 0.350 Interleukin-20 (IL-20) -0.02 0.787 0.07 0.708 Interleukin-4 (IL-4) -0.05 0.787 0.15 0.708